301234.SHE ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD.
- Market cap
- CNY 8.98B
- P/E
- 507.7x
- P/B
- 11.73x
- ROE
- 3.1%
- Dividend yield
- 0.23%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301234.SHE undervalued?
Graham numberThe Graham number of ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. fundamental analysis
No fundamental analysis for ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. yet.
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD.
Anhui Hongyu Wuzhou Medical Manufacturer Co.,LTD. engages in the research, development, production, and sale of disposable sterile infusion medical devices in China. The company offers safety hypodermic needle, safety blood collection needle, safety blood collection set, conventional syringes, hypodermic and blood collection needle, and insulin syringes and pen needles, as well as infusion, blood administration, burette, and scalp vein sets. It also exports its products to a…
Full company profileANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 487M | 471M | 513M | 547M | 534M | 477M | 458M | 400M |
| Gross Profit | 108M | 95.9M | 116M | 123M | 114M | 85.0M | 66.8M | 68.3M |
| Operating Income | 69.3M | 70.2M | 85.8M | 69.5M | 64.8M | 40.5M | 18.6M | 30.2M |
| EBITDA | 88.0M | 83.3M | 85.6M | 96.9M | 102M | 85.2M | 61.8M | 27.3M |
| Net Income | 52.9M | 56.7M | 68.4M | 70.9M | 60.3M | 40.0M | 18.9M | 23.4M |
| EPS | 1.04 | 1.11 | 1.34 | 1.04 | 0.89 | 0.59 | 0.28 | 0.34 |
| Balance Sheet | ||||||||
| Total Assets | 320M | 327M | 383M | 845M | 848M | 873M | 869M | 865M |
| Total Liabilities | 182M | 133M | 120M | 121M | 98.5M | 110M | 108M | 100M |
| Shareholders' Equity | 138M | 194M | 263M | 723M | 750M | 762M | 761M | 765M |
| Cash & Short-term Investments | 67.0M | 49.3M | 43.3M | 104M | 271M | 156M | 81.1M | 58.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | 88.1M | 55.0M | 62.6M | 111M | 81.8M | 88.9M | 73.4M | - |
| Capital Expenditure | 23.6M | 33.7M | 56.5M | 164M | 70.9M | 37.0M | 19.8M | 45.5M |
| Free Cash Flow | 64.5M | 21.3M | 6.07M | -52.5M | 10.9M | 51.9M | 53.6M | 7.37M |
| Ratios | ||||||||
| ROE | 38.4% | 29.2% | 26.0% | 9.8% | 8.0% | 5.2% | 2.5% | 3.1% |
| ROA | 16.6% | 17.3% | 17.9% | 8.4% | 7.1% | 4.6% | 2.2% | 2.7% |
| Net Profit Margin | 10.9% | 12.0% | 13.3% | 13.0% | 11.3% | 8.4% | 4.1% | 5.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. dividends
- Dividend yield
- 0.23%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 107.8%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.4M | 0.30 | 107.8% |
| 2024 | CNY 27.2M | 0.40 | 68.0% |
| 2023 | CNY 34.0M | 0.50 | 56.4% |
| 2022 | CNY 620K | 0.01 | 0.9% |
| 2021 | CNY 1.03M | 0.02 | 1.5% |
| 2020 | CNY 36.1M | 0.71 | 63.5% |
| 2019 | CNY 13.1M | 0.26 | 24.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD.
- Insiders 69.14%
- Institutions 1.26%
- Public & others 29.60%
- Shares outstanding 68.0M
- Free float 20.6M
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. company profile
- Company name
- ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD.
- Ticker
- 301234.SHE
- ISIN
- CNE100005GW5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 856
- Fiscal year end
- December
- Address
- No. 2 Guanyin Road, Anqing, China, 246400
- Phone
- 86 55 6512 9669
- Website
- hongyu-wuzhou.com
About ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD.
Anhui Hongyu Wuzhou Medical Manufacturer Co.,LTD. engages in the research, development, production, and sale of disposable sterile infusion medical devices in China. The company offers safety hypodermic needle, safety blood collection needle, safety blood collection set, conventional syringes, hypodermic and blood collection needle, and insulin syringes and pen needles, as well as infusion, blood administration, burette, and scalp vein sets. It also exports its products to approximately 80 countries. The company was founded in 2011 and is headquartered in Anqing, China.
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. management
5- Mr. Hongyu ZhangGM & Director · born 1968
- Ms. Yu JiHead of Accounting Department & CFO · born 1989
- Ms. Lanlan PanDeputy GM, Board Secretary & Employee Director · born 1968
- Mr. Hui JinDeputy General Manager · born 1965
- Mr. Jian Ming LiuDeputy General Manager · born 1970